Creon® (DR/GR) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02415959 (ClinicalTrials.gov) | March 2015 | 19/3/2015 | Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis | A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis | Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis | Drug: Creon IR;Drug: Creon® (DR/GR) | Abbott | AbbVie;LKF Laboratorium für Klinische Forschung GmbH;Analytical Biochemical Laboratory;Parexel;Datamap;Linical Co., Ltd. | Completed | 12 Years | N/A | All | 70 | Phase 2 | Czech Republic;Hungary;Poland;Spain |